Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Aarti Sawant Basak"'
Autor:
Aarti Sawant‐Basak, Arthur J. Bergman, Jessica Mancuso, Sakambari Tripathy, James R. Gosset, Laure Mendes da Costa, William P. Esler, Roberto A. Calle
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 2, Pp n/a-n/a (2024)
Abstract Co‐administration of clesacostat (acetyl‐CoA carboxylase inhibitor, PF‐05221304) and ervogastat (diacylglycerol O‐acyltransferase inhibitor, PF‐06865571) in laboratory models improved non‐alcoholic fatty liver disease (NAFLD)/non
Externí odkaz:
https://doaj.org/article/ea4079a3b1344ca986312423c445ad90
Autor:
Jian Lin, Francois Gaudreault, Nathaniel Johnson, Zhiwu Lin, Parya Nouri, Theunis C. Goosen, Aarti Sawant‐Basak
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 9, Pp 2184-2194 (2022)
Abstract PF‐05251749 is a dual inhibitor of casein kinase 1 δ/ε under clinical development to treat disruption of circadian rhythm in Alzheimer's and Parkinson's diseases. In vitro, PF‐05251749 (0.3–100 μM) induced CYP3A in cryopreserved hum
Externí odkaz:
https://doaj.org/article/3acb9acbeb5d41ab87d83417884bfb90
Autor:
Aarti Sawant‐Basak, Laigao Chen, Peter Lockwood, Tracey Boyden, Angela C. Doran, Jessica Mancuso, Kenneth Zasadny, Timothy McCarthy, Evan D. Morris, Richard E. Carson, Irina Esterlis, Yiyun Huang, Nabeel Nabulsi, Beata Planeta, Terence Fullerton
Publikováno v:
Biopharmaceutics & Drug Disposition. 44:48-59
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b8e431e5e4c75cacd4fd4793f7fa605
https://doi.org/10.1002/bdd.2351
https://doi.org/10.1002/bdd.2351
Autor:
Marion T. Kasaian, A. David Rodrigues, Regis Doyonnas, Bhagwat Prasad, Aarti Sawant-Basak, Matthew P. Lech, Nikolaos Tsamandouras
Publikováno v:
Drug Metabolism and Disposition. 46:1581-1587
Intestinal disposition of small molecules involves interplay of drug metabolizing enzymes (DMEs), transporters, and host-microbiome interactions, which has spurred the development of in vitro intestinal models derived from primary tissue sources. Suc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::464ef4e1f658fa92c87a9b63b21bd5a0
https://doi.org/10.1124/dmd.118.082784
https://doi.org/10.1124/dmd.118.082784
Autor:
Angela C. Doran, Peter Lockwood, Thomas A. Comery, R. Scott Obach, Aarti Sawant-Basak, Hongying Gao, Jessica Mancuso, Susanna Tse, Klaas Schildknegt
Publikováno v:
Drug Metabolism and Disposition. 46:934-942
SAM-760 [(2-methyl-1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-benzo[d]imidazole)], a 5HT6 antagonist, was investigated in humans for the treatment of Alzheimer's disease. In liver microsomes and recombinant cytochrome P450 (P450) isozymes, SAM-760 was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f12639f175a31b7dcb982ff48b0dc0c2
https://doi.org/10.1124/dmd.118.080457
https://doi.org/10.1124/dmd.118.080457
Autor:
Mark J. Majchrzak, Aarti Sawant-Basak, Christopher J. Schmidt, Nawshaba Nawreen, Thomas Allen Chappie, Rebecca E. O’Connor, Michelle Vanase-Frawley, Keith Dlugolenski, David Horton, David P. Nguyen, Bethany L. Kormos, Ramalakshmi Yegna Chandrasekaran, Travis T. Wager, Nancy C. Stratman, Elizabeth R. Dunn-Sims, Brian Samas, Andy N. Mead, Cathleen Hsu
Publikováno v:
ACS Chemical Neuroscience. 8:165-177
Dopamine receptor antagonism is a compelling molecular target for the treatment of a range of psychiatric disorders, including substance use disorders. From our corporate compound file, we identified a structurally unique D3 receptor (D3R) antagonist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::233def4cf409b94edafff8b7059d5f86
https://doi.org/10.1021/acschemneuro.6b00297
https://doi.org/10.1021/acschemneuro.6b00297
Autor:
Beata Planeta, Shu-fei Lin, Aarti Sawant-Basak, Jean-Dominique Gallezot, Donna Palumbo, Richard E. Carson, Jing Liu, Carolyn Rowinski, Yiyun Huang, Nabeel Nabulsi, David Labaree, Kristin Chidsey, Xiaoxi Li, Timothy J. McCarthy, Jim Ropchan, Anne W. Schmidt
Publikováno v:
Journal of Cerebral Blood Flow & Metabolism. 37:1095-1107
Measurements of drug occupancies using positron emission tomography (PET) can be biased if the radioligand concentration exceeds “tracer” levels. Negative bias would also arise in successive PET scans if clearance of the radioligand is slow, resu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86812448f2c9d31331398daec220cb9d
https://doi.org/10.1177/0271678x16650697
https://doi.org/10.1177/0271678x16650697
Autor:
Yiyun Huang, David Labaree, Aarti Sawant-Basak, Nabeel Nabulsi, Jean-Dominique Gallezot, Donna Palumbo, Laigao Chen, Douglas K. Spracklin, Anne W. Schmidt, Elaine E. Tseng, Timothy J. McCarthy, Christopher L. Shaffer, Richard E. Carson
Publikováno v:
Xenobiotica. 47:119-126
1. Unbound brain drug concentration (Cb,u), a valid surrogate of interstitial fluid drug concentration (CISF), cannot be directly determined in humans, which limits accurately defining the human Cb,u:Cp,u of investigational molecules. 2. For the H3R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23743ffeeabebda6e538afe126e90b33
https://doi.org/10.3109/00498254.2016.1166531
https://doi.org/10.3109/00498254.2016.1166531
Autor:
R. Scott Obach, Aarti Sawant-Basak
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 46(11)
This commentary summarizes expert mini-reviews and original research articles that have been assembled in a special issue on novel models of drug metabolism and disposition. The special issue consists of research articles or reviews on novel static o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6eb7ccd6f820210c9e22f1480f4ec4c0
https://pubmed.ncbi.nlm.nih.gov/30333205
https://pubmed.ncbi.nlm.nih.gov/30333205
Autor:
Aarti, Sawant-Basak, R Scott, Obach, Angela, Doran, Peter, Lockwood, Klaas, Schildknegt, Hongying, Gao, Jessica, Mancuso, Susanna, Tse, Thomas A, Comery
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 46(7)
SAM-760 [(2-methyl-1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-benzo[d]imidazole)], a 5HT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::888ea6f505d4ba0405fbd8ec06a7a1fe
https://pubmed.ncbi.nlm.nih.gov/29695615
https://pubmed.ncbi.nlm.nih.gov/29695615